Dr. Madi Madiyalakan reports

QUEST RECEIVES CASH DIVIDEND PAYMENT FROM ONCOQUEST

Quest Pharmatech Inc. has received a cash dividend payment from OncoQuest Inc. (one of Quest's investee companies) of approximately $685,000. Quest has a 42.5-per-cent ownership interest in OncoQuest. The dividend income will be used by Quest for general corporate purposes.

About Quest Pharmatech Inc.

Quest Pharmatech is a publicly traded, Canadian-based biopharmaceutical company developing products to improve the quality of life. The company has a 42.5-per-cent ownership interest in OncoQuest, which sold its immunotherapy technology assets to Korea's Dual Industrial Co. Ltd. in April, 2020. Quest also has a 23-per-cent ownership interest in OncoVent, a Chinese joint venture developing antibody-based immunotherapeutic products for cancer for the greater China territory. Quest is also developing proprietary MAb AR 9.6 targeting truncated MUC16 as theranostic agents for cancer. AR 9.6 was licensed from University of Nebraska and currently is in late preclinical stage.

We seek Safe Harbor.